The invention relates to a steroid derivative which steroidal skeleton is bound at carbon atom 17 to a spiromethylene ring of the formula: ##STR1## wherein Ra and Rb are independently selected from the group consisting of hydrogen, methyl, and halogen; m is 1 or 2; and the asterisk denotes carbon atom 2 of the spiromethylene ring which is carbon atom 17 (or carbon atom 17α of a homosteroid skeleton) of the steroid. The steroids have progestational or antiprogestational activity.
|
2. A 17-spiromethylene steroid having the formula: ##STR9## wherein: Ra and Rb are independently selected from the group consisting of hydrogen, methyl, and halogen;
m is 2; X is CHR1 or a bond; R1 is H, C3, CN, OH, Oacyl, F, spirocyclopropyl; or together with R2 or R10 is CH2, CF2, or OC(C3)2 O; or together with R11 is CH2 O; R2 is H, alkyl, CH2 OH, CN, OH, Oacyl, F, or spirocyclopropyl; or together with R1 or R3 is a group indicated in the definitions of R1 and R3, respectively; or together with R10 is CH2 ; or together with R2' is ═CH--R, wherein R is H, OH, Oalkyl, or Oacyl; R2' is H, alkyl, or CN; or together with R2 is a group indicated in the definition of R2 ; R3 is H2, O, NOH, NOalkyl, NOacyl, (H,OH), (H,Oacyl), (O,Oalkyl), (H,Ocycloalkyl), or 1-pyrrolidinyl; or (O,alkynyl) when X is a bond; or R2 and R3 together with C2 and C3 of the steroid skeleton form an oxazole: ##STR10## or a diazole: ##STR11## R4 is H, alkyl, halogen, CN, N3, OH, phenylmethyl, phenylthiomethyl, methylthio, or alkylcarbonylthio; R5 is H or OH; one of R6 and R7 is H, alkyl, CF3, CH2 F, OH, halogen, CN, Oalkyl, Oacyl, Sacyl, CH2 OH, NO2, COOalkyl, OSO2 alkyl, or spirocyclopropyl, and the other is H; or R6 together with R7 is CH2, CF2, O, or CHClCHCl; or R6 together with R6' is CH2 when R7 is H; or R7 together with R7' is CH2 or CF2 when R6 is H; R6' is H; or H or alkyl when R6 is alkyl; or H or halogen when R6 is halogen; or together with R6 is a group indicated in the definition of R6 ; or H or F when R6 and R7 together are CF2 ; R7' is H; or H or alkyl when R7 is alkyl; or H or halogen when R7 is halogen; or together with R7 is a group indicated in the definition of R7 ; R8 is H or CH3 ; R9 is H, halogen, OH, or methyl; or together with R10 is CH2 or O; R10 is H, alkyl, halogen-substituted alkyl, alkenyl, alkynyl, halogen, OH, OOH, OOacyl, Oalkyl, Oalkynyl, amino, alkyl-substituted amino, NHacyl, aminomethyl, alkyl-substituted aminomethyl, CHO, COOH, COOalkyl, CH2 OH, CH2 Oacyl, or CH2 CH2 OH; or together with R1, R9, or R11 is a group indicated in the definition of R1, R9, or R11 respectively; or together with C10, C9, C11 of the steroid skeleton and R11, when R11 is a substituted or unsubstituted phenyl, naphthyl, pyridinyl, pyrimidinyl, or thienyl, as defined for R11 below, is a 6-membered ring; R11 is H, alkyl, cycloalkyl, alkenyl, alkynyl, phenylethyl, phenylethynyl, naphthylethynynl, pyridinylethynyl, pyrimidinylethynyl, thienylethynyl, halogen-substituted alkyl, alkyl-substituted aminoalkyl, halogen, CH2 OCH3, OH, OOH, Oalkyl, Oacyl, SH, Salkyl, N3, Si(CH3)2, phenyl, naphthyl, pyridinyl, pyrimidinyl or thienyl, wherein any of said phenyl, naphthyl, pyridinyl, pyrimidinyl and thienyl moieties are optionally substituted with alkyl, Oalkyl, halogen, acyl, and/or OH, and wherein said phenyl is optionally substituted with amino, alkyl-substituted amino or an N-oxide of the amino or alkyl-substituted amino group, vinyl, methylthio, oxazole that is optionally substituted with an alkyl, CN, CHO, CHNOH, CONR'R", R' and R" being independently H, alkyl or hydroxy-substituted alkyl; or R11 together with R11' is CH2, CF2, or CHF; or together with R10 is OC═O or OCHF; or together with R1 is OCH2 ; or together with R13 is OCH2 or CH2 CH2 CH2 ; R11' is H, alkyl, cycloalkyl, alkenyl, alkynyl, phenylethyl, phenylethynyl, naphthylethynynl, pyridinylethynyl, pyrimidinylethynyl, thienylethynyl, halogen-substituted alkyl, alkyl-substituted aminoalkyl, halogen, CH2 OCH3, OH, OOH, Oalkyl, Oacyl, SH, Salkyl, N3, Si(CH3)2, phenyl, naphthyl, pyridinyl, pyrimidinyl or thienyl, wherein any of said phenyl, naphthyl, pyridinyl, pyrimidinyl and thienyl moieties are optionally substituted with alkyl, Oalkyl, halogen, acyl, and/or OH, and wherein said phenyl is optionally substituted with amino, alkyl-substituted amino or an N-oxide of the amino or alkyl-substituted amino group, vinyl, methylthio, oxazole that is optionally substituted with an alkyl, CN, CHO, CHNOH, CONR'R", R' and R" being independently H, alkyl or hydroxy-substituted alkyl; or R11' together with R11 is a group indicated in the definition of R11 ; or together with R13 is CH2 CH2 CH2 when R11 is H; R13 is H, alkyl, alkenyl, alkynyl, fluoro-substituted alkyl, phenyl, or cycloalkyl; or R13 together with R11, R11', or R16 is CH2 CH2 CH2 ; one of R15 and R16 is H, OH, Oalkyl, Oacyl, halogen, alkyl, or spirocyclopropyl, and the other is H; or R15 together with R16 is CH2 or CClF; R15' is H; or together with R15 is CH2 or F2 when R16 is H; R16' is H; or together with R16 is CH2 or F2 when R15 is H; and wherein the twitched lines represent an α or β bond; and the dotted lines represent up to four optional non-adjacent bonds; or pharmaceutically acceptable salts thereof.
1. A 17-spiromethylene steroid having the formula: ##STR6## wherein: Ra and Rb are independently selected from the group consisting of hydrogen, methyl, and halogen;
m is 1; X is CHR1 or a bond; R1 is H, CH3, CN, OH, Oacyl, F, spirocyclopropyl; or together with R2 or R10 is CH2, CF2, or OC(CH3)2 O; or together with R11 is CH2 O; R2 is H, alkyl, CH2 OH, CN, OH, Oacyl, F, or spirocyclopropyl; or together with R1 or R3 is a group indicated in the definitions of R1 and R3, respectively; or together with R10 is CH2 ; or together with R2' is ═CH--R, wherein R is H, OH, Oalkyl, or Oacyl; R2 ' is H, alkyl, or CN; or together with R2 is a group indicated in the definition of R2 ; R3 is H2, O, NOH, NOalkyl, NOacyl, (H,OH), (H,Oacyl), (O,Oalkyl), (H,Ocycloalkyl), or 1-pyrrolidinyl; or (O,alkynyl) when X is a bond; or R2 and R3 together with C2 and C3 of the steroid skeleton form an oxazole: ##STR7## or a diazole: ##STR8## R4 is H, alkyl, halogen, CN, N3, OH, phenylmethyl, phenylthiomethyl, methylthio, or alkylcarbonylthio; R5 is H or OH; one of R6 and R7 is H, alkyl, CF3, CH2 F, OH, halogen, CN, Oalkyl, Oacyl, Sacyl, CH2 OH, NO2, COOalkyl, OSO2 alkyl, or spirocyclopropyl, and the other is H; or R6 together with R7 is CH2, CF2, O, or CHClCHCl; or R6 together with R6' is CH2 when R7 is H; or R7 together with R7' is CH2 or CF2 when R6 is H; R6' is H; or H or alkyl when R6 is alkyl; or H or halogen when R6 is halogen; or together with R6 is a group indicated in the definition of R6 ; or H or F when R6 and R7 together are CF2 ; R7 ' is H; or H or alkyl when R7 is alkyl; or H or halogen when R7 is halogen; or together with R7 is a group indicated in the definition of R7 ; R8 is H or CH3 ; R9 is H, halogen, OH, or methyl; or together with R10 is CH2 or O; R10 is H, alkyl, halogen-substituted alkyl, alkenyl, alkynyl, halogen, OH, OOH, OOacyl, Oalkyl, Oalkynyl, amino, alkyl-substituted amino, NHacyl, aminomethyl, alkyl-substituted aminomethyl, CHO, COOH, COOalkyl, CH2 OH, CH2 Oacyl, or CH2 CH2 OH; or together with R1, R9, or R11 is a group indicated in the definition of R1, R9, or R11 respectively; or together with C10, C9, C11 of the steroid skeleton and R11, when R11 is a substituted or unsubstituted phenyl, naphthyl, pyridinyl, pyrimidinyl, or thienyl, as defined for R11 below, is a 6-membered ring; R11 is H, alkyl, cycloalkyl, alkenyl, alkynyl, phenylethyl, phenylethynyl, naphthylethynynl, pyridinylethynyl, pyrimidinylethynyl, thienylethynyl, halogen-substituted alkyl, alkyl-substituted aminoalkyl, halogen, CH2 OCH3, OH, OOH, Oalkyl, Oacyl, SH, Salkyl, N3, Si(CH3)2, phenyl, naphthyl, pyridinyl, pyrimidinyl or thienyl, wherein any of said phenyl, naphthyl, pyridinyl, pyrimidinyl and thienyl moieties are optionally substituted with alkyl, Oalkyl, halogen, acyl, and/or OH, and wherein said phenyl is optionally substituted with amino, alkyl-substituted amino or an N-oxide of the amino or alkyl-substituted amino group, vinyl, methylthio, oxazole that is optionally substituted with an alkyl, CN, CHO, CHNOH, CONR'R", R' and R" being independently H, alkyl or hydroxy-substituted alkyl; or R11 together with R11' is CH2, CF2, or CHF; or together with R10 is OC═O or OCHF; or together with R1 is OCH2 ; or together with R13 is OCH2 or CH2 CH2 CH2 ; R11' is H, alkyl, cycloalkyl, alkenyl, alkynyl, phenylethyl, phenylethynyl, naphthylethynynl, pyridinylethynyl, pyrimidinylethynyl, thienylethynyl, halogen-substituted alkyl, alkyl-substituted aminoalkyl, halogen, CH2 O CH3, OH, OOH, Oalkyl, Oacyl, SH, Salkyl, N3, Si(CH3)2, phenyl, naphthyl, pyridinyl, pyrimidinyl or thienyl, wherein any of said phenyl, naphthyl, pyridinyl, pyrimidinyl and thienyl moieties are optionally substituted with alkyl, Oalkyl, halogen, acyl, and/or OH, and wherein said phenyl is optionally substituted with amino, alkyl-substituted amino or an N-oxide of the amino or alkyl-substituted amino group, vinyl, methylthio, oxazole that is optionally substituted with an alkyl, CN, CHO, CHNOH, CONR'R", R' and R" being independently H, alkyl or hydroxy-substituted alkyl; or R11' together with R11 is a group indicated in the definition of R11 ; or together with R13 is CH2 CH2 CH2 when R11 is H; R13 is H, alkyl, alkenyl, alkynyl, fluoro-substituted alkyl, phenyl, or cycloalkyl; or R13 together with R11, R11', or R16 is CH2 CH2 CH2 ; one of R15 and R16 is H, OH, Oalkyl, Oacyl, halogen, alkyl, or spirocyclopropyl, and the other is H; or R15 together with R16 is CH2 or CClF; R15' is H; or together with R15 is CH2 or F2 when R16 is H; R16' is H; or together with R16 is CH2 or F2 when R15 is H; and wherein the twitched lines represent an α or β bond; and the dotted lines represent up to four optional non-adjacent bonds; or pharmaceutically acceptable salts thereof.
3. The steroid of
X is CHR1 ; R1, R2, R2', R4, R5, R6', R7', R8, R9, R15, and R16' are H; R3 is H2, O, (H,OH), or NOH; R6 and R7 are H; or one of R6 and R7 is H and the other is CH3 ; or R6 together with R7 is CH2 ; R10 is H or CH3 ; or together with R1, CH2 ; R11 is H, alkyl, vinyl, ethynyl, phenylethyl, or phenyl, which is substituted at its 4 position with CN, acyl, alkylthio, alkoxalkyl, amino or alkyl-substituted amino, or an N-oxide of the amino or alkyl-substituted amino; or R11 together with R11' is CH2, CH2, or CHF; R11' is H, alkyl, vinyl, ethynyl, phenylethynyl, phenyl which is substituted at its 4 position with CN, acyl, alkoxalkyl, amino or alkyl-substituted amino, or an N-oxide thereof; or R11 together with R11 is CH2, CF2, or CHF; R13 is alkyl; R15 and R16 are H; or together are CH2 ; the 13 bond is β and the 14 bond is α; and positions 4-5; 4-5; 8-9; 4-5,9-10; 4-5,15-16; 5-10; 3-4; or 4-5,6-7 of the steroid skeleton may have an additional bond.
4. The steroid of
X is CH1 ; R1, R2, R2', R4, R5, R6', R7', R8, R9, R10, R13', R15, R15', R16, and R16', are H; R3 is H2, O, (H,OH), or NOH; R6 and R7 are H; or one of R6 and R7 is H and the other is CH3 ; or R6 together with R7 is CH2 ; R11 is H, CH3, CH2 ═CH, or phenyl, the 4 position of which is substituted with dimethylamino, vinyl, acetyl, methoxy, methylthio, oxazole, CN, CHO, CHNOH, or CONR'R", R' and R" being independently H, alkyl, or hydroxy-substituted alkyl; or R11 together with R11' is CH2, CHF, or CF2 ; R11' is H or together with R11 CH2, CHF, or CF2 ; R13 is CH3, C2 H5, or C3 H7 ; the 13 bond is β and the 14 bond is α; and positions 4-5; 4-5,8-9; 4-5,9-10; 4-5,15-16; 5-10; 3-4; or 4-5,6-7 of the steroid skeleton may have an additional bond.
5. The steroid of
X is CHR1 ; R1, R2, R2', R4, R5, R6, R6', R7, R7', R8, R9, R10, R11', R13', R15, R15', R16, and R16' are H; R3 is O; R11 is p-dimethylamino, p-acetyl or p-methylthio substituted phenyl; the 13 bond is β and the 14 bond is α; and positions 4-5, or 4-5,9-10 of the steroid skeleton have an additional bond.
6. A pharmaceutical preparation comprising a pharmaceutically acceptable amount of the steroid of
7. The steroid of
X is CHR1 ; R1, R2, R2', R4, R5, R6', R7', R8, R9, R10, R13', R15, R15', R16, and R16', are H; R3 is H2, O, (H,OH), or NOH; R6 and R7 are H; or one of R6 and R7 is H and the other is CH3 ; or R6 together with R7 is CH2 ; R11 is H, CH3, CH2 ═CH, or phenyl, the 4 position of which is substituted with dimethylamino, vinyl, acetyl, methoxy, methylthio, oxazole, CN, CHO, CHNOH, or CONR'R", R' and R" being independently H, alkyl, or hydroxy-substituted alkyl; or R11 together with R11' is CH2, CHF, or CF2 ; R11' is H or together with R11 is CH2, CHF, or CF2 ; R13 is CH3, C2 H5, or C3 H7 ; the 13 bond is β and the 14 bond is α; and positions 4-5; 4-5,8-9; 4-5,9-10; 4-5,15-16; 5-10; 3-4; or 4-5,6-7 of the steroid skeleton may have an additional bond.
8. The steroid of
X is CHR1 ; R1, R2, R2', R4, R5, R6, R6', R7, R7', R8, R9, R10, R11', R13', R15, R15', R16, and R16' are H; R3 is O; R11 is p-dimethylamino, p-acetyl or p-methylthio substituted phenyl; the 13 bond is β and the 14 bond is α; and positions 4-5, or 4-5,9-10 of the steroid skeleton have an additional bond.
9. The steroid of
X is CHR1 ; R1, R2, R2', R4, R5, R6, R6', R7, R7', R8, R9, R10, R11', R13', R15, R15', R16, and R16', are H; R3 is O; R11 is p-dimethylamino, p-acetyl or p-methylthio substituted phenyl; the 13 bond is β and the 14 bond is α; and positions 4-5, or 4-5,9-10 of the steroid skeleton have an additional bond.
10. A method for preventing conception, comprising administering a pharmaceutical preparation according to
11. The steroid of
X is CHR1 ; R1, R2, R2', R4, R5, R6', R7', R8, R9, R15, and R16' are H; R3 is H2, O, (H,OH), or NOH; R6 and R7 are H; or one of R6 and R7 is H and the other is CH3 ; or R6 together with R7 is CH2 ; R10 is H or CH3 ; or together with R1, CH2 ; R11 is H, alkyl, vinyl, ethynyl, phenylethyl, or phenyl, which is substituted at its 4 position with CN, acyl, alkylthio, alkoxyalkyl, amino or alkyl-substituted amino, or an N-oxide of the amino or alkyl-substituted amino; or R11 together with R11' is CH2, CF2, or CHF; R11' is H, alkyl, vinyl, ethynyl, phenylethynyl, phenyl which is substituted at its 4 position with CN, acyl, alkoxyalkyl, amino or alkyl-substituted amino, or an N-oxide thereof; or R11' together with R11 is CH2, CF2, or CHF; R13 is alkyl; R15 and R16 are H; or together are CH2 ; the 13 bond is β and the 14 bond is α; and positions 4-5; 4-5,8-9; 4-5,9-10; 4-5,15-16; 5-10; 3-4; or 4-5,6-7 of the steroid skeleton may have an additional bond.
12. The steroid of
X is CHR1 ; R1, R2, R2', R4, R5, R6', R7', R8, R9, R10, R13', R15, and R15', R16, and R16', are H; R3 is H2, O, (H,OH), or NOH; R6 and R7 are H; or one of R6 and R7 is H and the other is CH3 ; or R6 together with R7 is CH2 ; R11 is H, CH3, CH2 ═CH, or phenyl, the 4 position of which is substituted with dimethylamino, vinyl, acetyl, method, methylthio, oxazole, CN, CHO, CHNOH, or CONR'R", R' and R" being independently H, alkyl, or hydroxy-substituted alkyl; or R11 together with R11' is CH2, CHF, or CF2 ; R11' is H or together with R11 CH2, CHF, or CF2 ; R13 is CH3, C2 H5, or C3 H7 ; the 13 bond is β and the 14 bond is α; and positions 4-5; 4-5,8-9: 4-5,9-10; 4-5,15-16; 5-10; 3-4; or 4-5,6-7 of the steroid skeleton may have an additional bond.
13. The steroid of
X is CHR1 ; R1, R2, R2', R4, R5, R6, R6', R7, R7', R8, R9, R10, R11', R13', R15, and R15', R16, and R16' are H; R3 is O; R11 is p-dimethylamino, p-acetyl or p-methylthio substituted phenyl; the 13 bond is β and the 14 bond is α; and positions 4-5, or 4-5,9-10 of the steroid skeleton have an additional bond.
14. A pharmaceutical preparation comprising a pharmaceutically acceptable amount of the steroid of
15. The steroid of
X is CHR1 ; R1, R2, R2', R4, R5, R6', R7', R8, R9, R10, R13', R15, R15', R16, and R16', are H; R3 is H2, O, (H,OH), or NOH; R6 and R7 are H; or one of R6 and R7 is H and the other is CH3 ; or R6 together with R7 is CH2 ; R11 is H, CH3, CH2 ═CH, or phenyl, the 4 position of which is substituted with dimethylamino, vinyl, acetyl, methoxy, methylthio, oxazole, CN, CHO, CHNOH, or CONR'R", R' and R" being independently H, alkyl, or hydroxy-substituted alkyl; or R11 together with R11' is CH2, CHF, or CF2 ; R11' is H or together with R11 is CH2, CHF, or CF2 ; R13 is CH3, C2 H5, or C3 H7 ; the 13 bond is β and the 14 bond is α; and positions 4-5; 4-5,8-9; 4-5,9-10; 4-5,15-16; 5-10; 3-4; or 4-5,6-7 of the steroid skeleton may have an additional bond.
16. The steroid of
X is CHR1 ; R1, R2, R2', R4, R5, R6, R6', R7, R7', R8, R9, R10, R11', R13', R15, R15', R16, and R16' are H; R3 is 0; R11 is p-dimethylamino, p-acetyl or p-methylthio substituted phenyl; the 13 bond is β and the 14 bond is α; and positions 4-5, or 4-5,9-10 of the steroid skeleton have an additional bond.
17. The steroid of
X is CHR1 ; R1, R2, R2', R4, R5, R6, R6', R7, R7', R8, R9, R10, R11', R13', R15, R15', R16, and R16' are H; R3 is O; R11 is p-dimethylamino, p-acetyl or p-methylthio substituted phenyl; the 13 bond is β and the 14 bond is α; and positions 4-5, or 4-5,9-10 of the steroid skeleton have an additional bond.
18. A method for preventing conception comprising administering a pharmaceutical preparation according to
19. A method for preventing conception comprising administering a pharmaceutical preparation according to
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The invention relates to 17-spiromethylene steroids, their preparation, pharmaceutical compositions containing the same, their use for contraception, and their use for the manufacture of a medicament.
Many progestational and antiprogestational steroids are known. It is now found that the activity of these steroids can be dramatically improved by the introduction of a new 17-substituent. It was found that this principle holds for both progestational and anti-progestational compounds, for example in comparison with steroids having the classical 17β-hydroxy-17α-ethynyl substituents.
The present invention relates to asteroid derivative of which carbon atom 17 (or carbon atom 17α of a homosteroid skeleton) is carbon atom 2 of a spiromethylene ring of the formula: ##STR2## wherein Ra and Rb are independently selected from the group consisting of hydrogen, methyl, and halogen; m is 1 or 2; and the asterisk denotes carbon atom 2 of the spiromethylene ring which is carbon atom 17 of the steroid (or carbon atom 17α of a homosteroid skeleton).
More specifically the steroid derivatives are claimed wherein the steroidal skeleton has the formula: ##STR3## wherein n is 0 or 1;
X is CHR1 or a bond;
R1 is H, CH3, CN, OH, Oacyl, F, spirocyclopropyl, or together with R2 or R10 CH2, CF2, or OC (CH3)2 O, or together with R11 CH2 O;
R2 is H, alkyl, CH2 OH, CN, OH, Oacyl, F, spirocyclopropyl, or together with R1 or R3 the groups indicated in the definitions of R1 and R3 respectively, or together with R10 CH2, or together with R2 '═CH--R,
wherein R is H, OH, Oalkyl, or Oacyl;
R2 ' is H, alkyl, or CN, or together with R2 the groups inculcated in the definition of R2 ;
R3 is H2, O, NOH, NOalkyl, NOacyl, (H,OH), (H,Oacyl), (O,Oalkyl), (H,Ocycloalkyl), or 1-pyrrolidinyl, or (O,alkynyl) when X is a bond, or R2 and R3 together with C2 and C3 of the steroid skeleton form an oxazole: ##STR4## or a diazole: ##STR5## R4 is H, alkyl, halogen, CN, N3, OH, phenylmethyl, phenylthiomethyl, methylthio, or alkylcarbonylthio;
R5 is H or OH;
One of R6 and R7 is H, alkyl, CF3, CH2 F, OH, halogen, CN, Oalkyl, Oacyl, Sacyl, CH2 OH, NO2, COOalkyl, OSO2 alkyl, or spirocyclopropyl, and the other is H, or R6 together with R7 is CH2, CF2, O, CHClCHCl, or R6 together with R6, is CH2 when R7 is H, or R7 together with R7, is CH2 or CF2 when R6 is H;
R6 ' is H, or H or alkyl when R6 is alkyl, or H or halogen when R6 is halogen, or together with R6 the groups indicated in the definition of R6, or H or F when R6 and R7 are together CF2 ;
R7 ' is H, or H or alkyl when R7 is alkyl, or H or halogen when R7 is halogen, or together with R7 the groups indicated in the definition of R7 ;
R8 is H or CH3 ;
R9 is H, halogen, OH, or methyl, or together with R10 CH2 or O;
R10 is H, alkyl, halogen-substituted alkyl, alkenyl, alkynyl, halogen, OH, OOH, OOacyl, Oalkyl, Oalkynyl, amino, alkyl-substituted amino, NHacyl, aminomethyl, alkyl-substituted aminomethyl, CHO, COOH, COOalkyl, CH2 OH, CH2 Oacyl, CH2 CH2 OH, or together with R1, R9, or R11 the groups indicated in the definition of R1, R9, and R11 respectively, or together with C10, C9, C11 of the steroid skeleton, and R11, when R11 is an aryl or heteroaryl, a 6-membered ring;
R11 is H, alkyl, cycloalkyl, alkenyl, alkynyl, phenylethyl, arylethynyl, heteroarylethynyl, halogen-substituted alkyl, alkyl-substituted aminoalkyl, halogen, CH2 O CH3, OH, OOH, Oalkyl, Oacyl, SH, Salkyl, N3, Si(CH3)2, aryl, or heteroaryl, or R11 together with R11' is CH2, CF2, or CHF, or together with R10 OC═O or OCHF, or together with R1 OCH2, or together with R13 OCH2 or CH2 CH2 CH2 ;
R11' is H, alkyl, cycloalkyl, alkenyl, alkynyl, phenylethyl, arylethynyl, heteroarylethynyl, halogen-substituted alkyl, alkyl-substituted aminoalkyl, halogen, CH2 OCH3, OH, OOH, Oalkyl, Oacyl, SH, Salkyl, N3, Si(CH3)2, aryl, or heteroaryl, or R11' together with R11 the groups indicated in the definition of R11, or together with R13 CH2 CH2 CH2 when R11 is H;
R13 is H, alkyl, alkenyl, alkynyl, fluoro-substituted alkyl, phenyl, or cycloalkyl, or R13 together with R11, R11', or R16 is CH2 CH2 CH2 ;
One of R15 and R16 is H, OH, Oalkyl, Oacyl, halogen, alkyl, or spirocyclopropyl, and the other is H, or R15 together with R16 is CH2 or CClF;
R15' is H or together with R15 CH2 or F2 when R16 is H;
R16' is H or together with R16 CH2 or F2 when R15 is H; the twitched lines represent an α or β bond; and the dotted lines represent up to four optional non-adjacent bonds; or pharmaceutically acceptable salts thereof.
Preferred steroid derivatives according to the invention have above-mentioned structure wherein:
n is 0;
X is CHR1 ;
R1, R2, R2', R4, R5, R6', R7', R8, R9, R15' and R16' are H;
R3 is H2, O, (H,OH), NOH;
R6 and R7 are H, or one of R6 and R7 is H and the other is CH3, or R6 together with R7 is CH2 ;
R10 is H or CH3, or together with R1 CH2 ;
R11 is H, alkyl, vinyl, ethynyl, phenylethynyl, phenyl which is substituted at its 4 position with CN, acyl, alkylthio, alkoxyalkyl, amino or alkyl-substituted amino, or an N-oxide of the amino or alkyl-substituted amino, or R11 together with R11' is CH2, CF2, or CHF;
R11' is H, alkyl, vinyl, ethynyl, phenylethynyl, phenyl which is substituted at its position 4 with CN, acyl, alkoxyalkyl, amino or alkyl-substituted amino, or an N-oxide thereof, or R11 ' together with R11 is CH2, CF2, or CHF;
R13 is alkyl;
R15 and R16 are each H or together CH2 ;
the 13 bond is β and the 14 bond is α; and positions 4-5; 4-5,8-9; 414 5,9-10; 4-5,15-16; 5-10; 3-4;
or 4-5,6-7 of the steroid skeleton may have an additional bond.
More preferred are the steroid derivatives having above-mentioned steroid structure wherein
Ra and Rb are independently selected from the group consisting of hydrogen, methyl, and halogen (preferably chlorine);
n is 0;
X is CHR1 ;
R1, R2, R2', R4, R5, R6', R7', R8, R9, R10, R13', R15, R15', R16, and R16' are H;
R3 is H2, O, (H,OH), or NOH;
R6 and R7 are H, or one of R6 and R7 is H and the other is CH3, or R6 together with R7 is CH2 ;
R11 is H, CH3, CH2 ═CH, or phenyl, the 4 position of which is substituted with dimethylamino, vinyl, acetyl, methoxy, methylthio, oxazole, CN, CHO, CHNOH, or CONR'R", R' and R" being independently H, alkyl, or hydroxy-substituted alkyl, or R11 together with R11 ' is CH2, CHF, or CF2 ;
R11' is H or together with R11 CH2, CHF, or CF2 ;
R13 is CH3, C2 H5, or C3 H7 ; the 13 bond is β and the 14 bond is α; and
positions 4-5; 4-5,8-9; 4-5,9-10; 4-5,15-16; 5-10; 3-4; or 4-5,6-7 of the steroid skeleton may have an additional bond.
Most preferred are the steroid derivatives wherein
n is 0;
X is CHR1 ;
R1, R2, R2', R4, R5, R6, R6', R7, R7', R8, R9, R10 , R11', R13', R15, R15', R16, and R16 ' are H;
R3 is O;
R11 is p-dimethylamino-, p-acetyl- or p-methylthio-substituted phenyl; the 13 bond is β and the 14 bond is α; and positions 4-5; 4-5,15-16; or 4-5,9-10 of the steroid skeleton have an additional bond.
The term alkyl means a branched or unbranched alkyl group having 1-8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl and the like. Preferred alkyl groups have 1-4 carbon atoms, and most preferred is the methyl group.
The term acyl means an acyl group derived from an alkylcarboxylic acid, the alkyl moiety having the previously given meaning.
The term alkenyl means a branched or unbranched alkenyl group having 2-6 carbon atoms. Preferred are alkenyl groups having 2-4 carbon atoms, like vinyl.
The term alkynyl means a branched or unbranched alkynyl group having 2-6 carbon atoms. Preferred are alkynyl groups having 2-4 carbon atoms, like ethynyl and 1-propynyl.
The term cycloalkyl means a cycloalkyl group having 3-8 carbon atoms like cyclopropyl, cyclopentyl and cyclohexyl.
The term halogen means fluorine, chlorine, bromine or iodine. Chlorine is the preferred halogen.
The term aryl means an aryl group like phenyl and naphthyl. Heteroaryl groups are heteroaromatic groups like pyridinyl, pyrimidinyl, thienyl or non-hetero-aromatics condensed with heteroaromatic groups. The aryl, heteroaryl and the phenyl groups used in the definition of the steroids of the inventions may be substituted by alkyl, Oalkyl, halogen, acyl and OH, as previously defined. The 11-phenyl group may also be substituted by amino, alkyl-substituted amino (preferably dimethylamino) or an N-oxide of the amino or alkyl-substituted amino group, vinyl, methylthio, oxazole, CN, CHO, CHNOH, CONR'R", R' and R" being independently H, alkyl, or hydroxy-substituted alkyl. The oxazole may also be an alkyl substituted oxazole.
The first orally active progestagens are norethisterone and derivatives thereof (U.S. Pat. No. 2,744,122). These first-generation progestagens have a 17α-ethynyl substituent and, apart from the 3-keto-delta4,5 no further substituents. These compounds have low progestagenic and low androgenic activity, and a low selectivity. Derivatives like norethisterone acetate and norethynodrel show very low estrogenic activity and low SHBG binding affinity. Second-generation progestagens were found having in addition a 18-methyl substituent. The most pertinent representative of this series is (levo)norgestrel (Belgian patent 623,844), which shows a better progestagenic activity, but also an increased androgenic activity. The selectivity is, therefore, not really improved with respect to the first-generation progestagens. The second-generation progestagens show no estrogenic activity, have a slight glucocorticoid activity and an increased SHBG binding affinity. The third-generation compounds have two additional substituents. The most remarkable representatives are desogestrel (U.S. Pat. No. 3,927,046) having an 11-methylene group, and gestodene (U.S. Pat. No. 4,081,537) having a delta15,16 double bond. These compounds have a better selectivity because their progestagenic activity is increased whereas their androgenic activity is similar or decreased with respect to levonorgestrel. Apart from their progestagenic activity, these compounds have at least one other hormonal activity, like glucocorticoid, antimineralocorticoid or estrogenic activity. The progestagenic compounds of the present invention are the fourth-generation of progestagens, having a pure progestagenic profile, without significant androgenic or other hormonal activities. Most compounds have no glucocorticoid activity, but some compounds having m is 2 show weak glucocorticoid activity. The compounds of this invention show an extremely strong binding affinity to the progesterone receptor.
The first-generation antiprogestagens are weakly active compounds like RMI 12,936 (Dutch pat. 7302540) and R-2323 (Gestrinone; U.S. Pat. No. 3,478,067). High anti-progestagenic activity was found with the second-generation of compounds, the lead compound of which is RU 486 (Mifepristone; U.S. Pat. No. 4,386,085). These compounds typically have an 11-aryl group, usually phenyl substituted with a para-dimethylamino group, and a 17α-1-propynyl group. Third-generation antiprogestational compounds have an additional substituent, mostly a 6- or 7-methyl group, and sometimes have a 17 spiro-ether group. Examples are Org 31710 (U.S. Pat. No. 4,871,724) and Org 31806 (U.S. Pat. No. 4,921,845). These compounds have diminished antiglucocortcoid activity. The antiprogestagenic compounds of the present invention are the fourth-generation of antiprogestagens, having a pure antiprogestagenic profile, without other significant hormonal activities. These compounds show an extremely strong binding affinity to the progesterone receptor.
The steroids of this invention, being a new generation of progestational and antiprogestational steroids, have improved affinity to the progesterone receptor, and/or have improved selectivity. These improved properties lead to better therapeutic effects on administering the compounds in patients.
The progestagenic and antiprogestagenic steroids of this invention can be used as contraceptives. They further exhibit the normal activities known for progestagens and antiprogestagens, such as treatment of menstrual disorders and hormone dependent tumors.
The steroids of the invention having m is 1 may be prepared by treating any 17-keto steroid (the reactive substituents of which are protected in a manner as usual for the protection of reactive groups) with alkylOCLi═C═CH2 wherein alkyl is a lower alkyl, preferably methyl, using, for example, the method of D. Gange and Ph. Magnus, J. Am. Chem. Soc. 100 (1978), 7747-7748. The 17-allenyl derivative obtained is treated with a base, preferably potassium tert-butoxide, in a suitable solvent (for example tert-butanol) or with silver nitrate to obtain the alkyl enol ether of a furan ring, carbon atom 2 of which is carbon atom 17 of the steroid skeleton (or carbon atom 17α for a homosteroid). Acid treatment of this compound gives the furan-3-one ring, carbon atom 2 of which is carbon atom 17 of the steroid skeleton (or carbon atom 17α for a homosteroid). When necessary, groups cleaved during the reaction are protected again, after which a Wittig, Wittig-Horner, or similar reaction is performed (for instance a Peterson reaction) with W-CHRa Rb wherein Ra and Rb have the previously given meanings, and W is a group suitable for a Wittig(like) or Peterson reaction, for instance a trimethyl- or triphenylphosphorane group (i.e. giving for instance (C6 H5)3 (halogen)PCHRa Rb or the Peterson reagent (CH3)3 Si(Mghalide)CHRa Rb), after which the remaining protective groups, when present, are removed and the compound obtained is optionally converted into a pharmaceutically acceptable salt.
The steroids of the invention having m is 2 may be prepared by treating any 17-keto steroid (other reactive substituents of which are protected in a manner as usual for the protection of reactive groups) with a pentenol derivative Ra Rb C═CLi--CH2 --CH2 --CH2 --OSi(alkyl)3, wherein Ra, Rb and alkyl have the previously given meanings, and which can be prepared by methods known in the art from the corresponding 2-bromo-5-hydroxy-1-pentene derivative, which is prepared, for example by the method of M. Mori et.al., J. Org. Chem. 48, 4058 (1983), followed by acid hydrolysis to give the 17,24-dihydroxy-steroid, after which the 24-hydroxy group is converted into a leaving group, for instance into a mesylate by treatment with methanesulfonylchloride, followed by ring closure to the 17-spiroether derivative by heating, for example, in toluene with a base such as s-collidine, after which the remaining protecting groups, when present, are removed and the compound obtained is optionally converted into a pharmaceutically acceptable salt.
The novel compounds may be isolated from the reaction mixture in the form of a pharmaceutically acceptable salt. The pharmaceutically acceptable salts may also be obtained by treating the free base with an organic or inorganic acid such as HCl, HBr, HI, H2 SO4, H3 PO4, acetic acid, propionic acid, glycolic acid, maleic acid, malonic acid, methanesulphonic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, and ascorbic acid.
The compounds of the invention may be administered enterally or parenterally, and for humans preferably in a daily dosage of 0,00025-10 mg per kg body weight. Mixed with pharmaceutically suitable auxiliaries, e.g. as described in the standard reference, Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their Manufacture) the compounds may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories. By means of pharmaceutically suitable liquids the compounds can also be applied as an injection preparation in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray. For making dosage units, e.g. tablets, the use of conventional additives such as fillers, colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used. Suitable carriers with which the compositions can be administered include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts.
The invention is further illustrated by the following examples.
(17α)-17,23-epoxy-24-norchola-4,20-dien-3-one was prepared from the known (17β)-4',5'-dihydrospiro[androst-4-ene-17,2'(3'H)-furan]-3,3'-dione (see D. Gange and Ph. Magnus, J. Am. Chem. Soc. 100, 7747-7748 (1978)) as follows:
(i) 6.64 g of the above-mentioned dione were dissolved in 13.5 ml of absolute ethanol under a nitrogen atmosphere. The reaction mixture was cooled in an ice bath and 7 ml of triethyl orthoformate and 70 mg of p-toluenesulfonic acid were added, after which the reaction mixture was stirred at 0°C for 5 h. The reaction was stopped by addition of 2 ml of triethylamine, and 4 ml of water were added. The resulting precipitate was filtered off, yielding 6.7 g (93%) of crystalline (17β)-3-ethoxy-4',5'-dihydrospiro[androsta-3,5-diene-17,2'(3'H)-furan ]-3'-one.
(ii) To a suspension of 18.7 g of potassium tert-butoxide in 290 ml of toluene under a nitrogen atmosphere were added 70 g of methyltriphenylphosphonium bromide. The mixture was refluxed for 45 min and then cooled. 6.7 g of the above-mentioned dienone were added and the mixture was refluxed for 2.5 h. The mixture was subsequently poured into ice-water, the toluene layer separated, washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The residue was chromatographed to afford 3.53 g (53%) of pure (17α)-17,23-epoxy-3-ethoxy-24-norchola-3,5,20-triene.
(iii) 3.53 g of the above-mentioned triene were dissolved in 36 ml of dichloromethane. To this solution were added 3.6 ml of 6N hydrochloric acid, and the mixture was stirred vigorously for 1.5 h. The reaction mixture was then poured into 360 ml of ice-water, the organic layer separated, dried over sodium sulfate and concentrated under reduced pressure to afford 2.46 g (75%) of (17α)-17,23-epoxy-24-norchola-4,20-dien-3-one after recrystallization from ethyl acetate. M.p. 127.2°C [α]D20 =+10.5° (c=0.99, chloroform).
In a manner similar to Example 1 were prepared
(17α)-17,23-epoxy-19,24-dinorchola-4,20-dien-3-one from (17β)-4',5'-dihydrospiro[estr-4-ene-17,2'(3'H)-furan]-3,3'-dione. M.p. 130.3°C [α]D20 =-47.4° (c=0.95, chloroform).
(17α)-17,23-epoxy-13-ethyl-18,19,24-trinorchola-4,20-dien-3-one from (17'β)-13'-ethyl-4,5-dihydrospiro[furan-2(3H),17'-gon[4]ene]-3,3'-dio ne. M.p. 135.0°C [α]D20 =-63.9° (c=1.04, chloroform).
(17α)-17,23-epoxy-11-methylene-19,24-dinorchola-4,20-dien-3-one from (17β)-4',5'-dihydro-11-methylenespiro[estr-4-ene-17,2'(3'H)-furan]-3, 3'-dione. M.p. 176 5°C [α]D20 =+64.3° (c=1.0, chloroform).
(17α)-17,23-epoxy-13-ethyl-11-methylene-18,19-24-trinorchola-4,20-die n-3-one from (17'β)-13'-ethyl-4,5-dihydro-11'-methylenespiro[furan-2(3H),17'-gon[4 ]ene]-3,3'-dione. M.p. 173.5°C [α]D20 =+50.7° (c=1.02, chloroform).
(17α)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one from (17β)-4',5'-dihydrospiro[estra-4,9-diene-17,2'(3'H)-furan]-3,3'-dione . The amorphous solid obtained melted at 136°C and had an [α]D20 of -280° (c=1.0, dioxane).
(17α)-17,23-epoxy-19,24-dinorchola-4,15,20-trien-3-one from (17β)-4',5'-dihydrospiro[estra-4,15-diene-17,2'(3'H)-furan]-3,3'-dion e. M.p. 137°C [α]D20 =-194.8° (c=1.0, chloroform).
(17α)-17,23-epoxy-13-ethyl-18,19,24-trinorchola-4,15,20-trien-3-one from (17'β)-13'-ethyl-4,5-dihydrospiro-[furan-2(3H),17'-gona-4,15-diene]-3 ,3'-dione. M.p. 136.4°C [α]D20 =-194.2° (c=0.99, chloroform).
(6α,17α)-17,23-epoxy-6-methyl-19,24-dinorchola-4,20-dien-3-one from (6α,17β)-4',5'-dihydro-6-methylspiro[estr-4-ene-17,2'(3'H)-fura n]-3,3'-dione. M.p. 105.9°C [α]D20 =-89.8° (c=1.035, dioxane).
(7α,17α)-17,23-epoxy-7-methyl-19,24-dinorchola-5(10),20-dien-3- one from (7α,17β)-4',5'-dihydro-7-methylspiro-[estr-5(10)-ene-17,2'(3'H) -furan]-3,3'-dione. Careful hydrolysis (oxalic acid in water) of the intermediate afforded the desired product as an amorphous solid. [α]D20 =+61.4° (c=0.975, chloroform).
(7α,17α)-17,23-epoxy-7-methyl-19,24-dinorchola-4,20-dien-3-one from (7α,17β)-4',5'-dihydro-7-methylspiro[estr-5(10)-ene-17,2'(3'H)- furan]-3,3'-dione. Hydrolysis under more strenuous conditions than in the previous reaction (hydrochloric acid in acetone) of the intermediate afforded the desired product. M.p. 127.6°C [α]D20 =-20.5° (c=1.0, chloroform).
(11β,17α)-17,23-epoxy-11-methyl-19,24-dinorchola-3,20-dien-4-one from (11β,17β)-4',5'-dihydro-11-methylspiro[estr-4-ene-17,2'(3'H)-fur an]-3,3'-dione. M.p. 181°C [α]D20 =-14.6° (c=1.0, chloroform).
(3'E,17β)-3'-ethylidene-4',5'-dihydrospiro[estr-4-ene-17,2'(3'H)-furan ]-3-one from (17β)-4',5'-dihydrospiro[estr-4-ene-17,2'(3'H)-furan]-3,3'-dione by treatment of the intermediate (17β)-3-ethoxy-4',5'-dihydrospiro-[estra-3,5-diene-17,2'(3'H)-furan]- 3'-one with ethyltriphenylphosphonium bromide. M.p. 143.6°C [α]D20 =-32.0° (c=1.0, chloroform).
(17α,21E)-21-chloro-17,23-epoxy-19,24-dinorchola-4,20-dien-3-one from (17β)-4',5'-dihydrospiro[estr-4-ene-17,2'(3'H)-furan]-3,3'-dione by treatment of the intermediate (17β)-3-ethoxy-4',5'-dihydrospiro[estra-3,5-diene-17,2'(3'H)-furan]-3 '-one with chloromethyltriphenylphosphonium chloride. M.p. 156.8°C [α]D20 =-16.8° (c=0.5, chloroform).
(17α)-17,23-epoxy-11-methylene-19,24-dinorchola-4,15,20-trien-3-one from (17β)-4',5'-dihydro-11-methylenespiro[estr-4-ene-17,2'(3'H)-furan]-3, 3'-dione. M.p. 183.7°C [α]D20 =-82.7° (c=1.0, chloroform).
(17α)-17,23-epoxy-13-ethyl-11-methylene-18,19,24-trinorchola-4,20-die ne was prepared directly from (17'β)-13'-ethyl-4,5-dihydro-11'-methylenespiro[furan-2(3H),17'-gon-4 -ene]-3-one by reaction with methyltriphenylphosphonium bromide as described in Example 1(ii). M.p. 138.4°C [α]D20 =+10.4° (c=0.99, chloroform).
In a similar manner as in Example 3 the following compounds were prepared
(5α,17α)-17,23-epoxy-13-ethyl-11-methylene-18,19,24-trinorchola -3,20-diene from (5'α,17'β)-13'-ethyl-4,5-dihydro-11'-methylenespiro[furan-2(3H) ,17'-gon-3-ene]-3-one. M.p. 136.8°C [α]D20 =+8.50° (c=1.02, chloroform).
(17α)-17,23-epoxy-11-methylene-19,24-dinorchola-4,20-diene from (17β)-4',5'-dihydro-11-methylenespiro[estr-4-ene-17,2'(3'H)-furan]-3' -one. M.p. 106.6°C [α]D20 =29.9° (c=1.0, chloroform).
(3'E,17β)-3'-ethylidene-4',5'-dihydro-11-methylenespiro[estr-4-ene-17, 2'(3'H)-furan]from (17β)-4',5'-dihydro-11-methylenespiro[estr-4-ene-17,2'(3'H)-furan]3'- one and ethyltrimethylphosphonium bromide. M.p. 139.8°C [α]D20 =+38.8° (c=1.0, chloroform).
E-[(17β)-4',5'-dihydro-3-oxospiro[estr-4-ene-17,2'(3'H)-furan]-3'-ylid ene]acetonitrile was obtained as follows:
(i) To a suspension of 1.2 g of lithium diisopropylamide in 30 ml of toluene 0.58 ml of acetonitrile were added at -40°C The mixture was then stirred at -20°C for 20 minutes, cooled to -50° C., and 358 mg of (17β)-3-ethoxy-4',5'-dihydrospiro[estra-3,5-diene-17,2'(3'H)-furan]-3 '-one were added. The mixture was allowed to warm to -10°C, and after 20 min poured into a saturated ammonium chloride solution. The organic layer was separated, washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was taken up in a mixture of 5 ml of acetone and 3 ml of 0.1N hydrochloric acid, stirred at room temperature for 2 h, and then partitioned between water and ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. Chromatography of the residue afforded 200 mg (54%) of (3'S,17β)-4',5'-dihydro-3'-hydroxy-3-oxospiro[estr-4-ene-17,2'(3'H)-f uran]-3'-acetonitrile.
(ii) 200 mg of the above-mentioned nitrile were dissolved in 10 ml of dry pyridine, and 0.07 ml of phosphorus oxychloride were added. The reaction mixture was refluxed for 30 min, cooled, and then poured into ice-water. The mixture was acidified with 2N hydrochloric acid and extracted with ethyl acetate. The extract was washed with water and with brine, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was chromatographed to afford 90 mg (47%) of E-[(17β)-4',5'-dihydro-3-oxospiro[estr-4-ene-17,2'(3,H)-furan]-3,-yli dene]acetonitrile. M.p. 193.5°C
(17α)-17,23-epoxy-19,24-dinorchola-5(10),20-dien-3-one was prepared from the known (17β)-3-methoxyspiro[estra-1,3,5(10)-triene-17,2'(3'H)-furan]-3'-one (see D. Gange and Ph. Magnus, J. Am. Chem. Soc. 100, 7746-7747 (1978)) as follows:
(i) The above-mentioned trienone was converted to (17α)-3-methoxy-17,23-epoxy-19,24-dinorchola-1,3,5(10),20-tetraene as described for Example 1
(ii) 5 g of the tetraene were then dissolved in 350 ml of tetrahydrofuran and this solution added to a solution of 4.3 g of lithium dissolved in 430 ml of ammonia which was maintained at -33°C After 4 h at this temperature 50 ml of ethanol were slowly added and the ammonia allowed to evaporate. The residue was partitioned between water and dichloromethane, the organic layer washed with water, dried over magnesium sulfate and concentrated under reduced pressure, affording after recrystallization from ethanol 2.12 g of (17α)-3-methoxy-17,23-epoxy-19,24-dinorchola-2,5(10),20-triene.
(iii) 2.12 g of the above-mentioned triene were suspended in 155 ml of methanol to which suspension was added a solution of 2.33 g of oxalic acid in 30 ml of water. The mixture was stirred overnight at ambient temperature, after which diethyl ether was added. The ethereal layer was separated and washed three times with a saturated solution of sodium bicarbonate and once with water, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was chromatographed to afford 0.7 g of the desired dienone as an amorphous solid. [α]D20 =+84° (c=0.935, chloroform).
(17α)-17,23-epoxy-19,24-dinorchola-4,20-dien-3-one oxime was prepared from (17α)-17,23-epoxy-19,24-dinorchola-4,20-dien-3-one as follows: a mixture of 0.7 g of hydroxylamine hydrochloride, 0.56 g of potassium hydroxide and 0.44 g of the starting ketone in 50 ml of ethanol was refluxed overnight. Subsequently, the solvent was removed under reduced pressure and the residue partitioned between water and dichloromethane. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to afford after recrystallization from diisopropyl ether 0.23 g of a 3:1 mixture of the E and Z oxime. M.p. 269.5°C [α]D20 =43.6° (c=0.975, chloroform).
(3β,17α)-17,23-epoxy-19,24-dinorchola-4,20-dien-3-ol was prepared from (17α)-17,23-epoxy-19,24-dinorchola-4,20-dien-3-one as follows: 0.65 g of the ketone were dissolved in 10 ml of methanol under a nitrogen atmosphere. 80 mg of sodium borohydride were added and the mixture was stirred at ambient temperature for 1.5 h. The reaction mixture was then partitioned between water and dichloromethane. The organic layer was washed with 0.1N hydrochloric acid and with brine, and dried over sodium sulfate. Removal of the solvent under reduced pressure afforded 0.62 g of crude material, from which the above alcohol could be obtained by crystallization from ethyl acetate. M.p. 132.3°C [α]D20 =-58.9° (c=1.36, chloroform). Column chromatography of the mother liquor of the above reaction afforded (3α,17α)-17,23-epoxy-19,24-dinorchola-4,20-dien-3-ol as an amorphous solid. [α]D20 =+11.0° (c=1.14, chloroform).
(3β,17α)-17,23-epoxy-19,24-dinorchola-4,20-dien-3-ol acetate (ester) was prepared from (35,17α)-17,23-epoxy-19,24-dinorchola-4,20-dien-3-ol, mentioned above, as follows: 0.81 g of the alcohol were dissolved in 4 ml of pyridine and 1 ml of acetic anhydride was added. The mixture was stirred overnight under a nitrogen atmosphere and then coevaporated three times with toluene; the residue was partitioned between water and dichloromethane; the latter was dried over sodium sulfate and concentrated under reduced pressure. The residue was recrystallized from ethyl acetate to afford 0.55 g of the ester. M.p. 177.7°C [α]D20 =-96.6° (c=1.02, chloroform).
Alternatively, the compounds described in Examples 1-9 can be prepared as follows: The conversion of e.g. (17β)-3-ethoxy-4',5'-dihydrospiro[androsta-3,5-diene-17,2'(3'H)-furan ]-3'-one to (17α)-17,23-epoxy-24-norchola-4,20-dien-3-one could be effected by treatment of the former with trimethylsilylmethylmagnesium chloride, followed by acid treatment, which not only produces the desired olefin but also effects hydrolysis of the acid-labile protecting group. For the selective transformation of the 3'-carbonyl group, the ketone at C-3 of the steroid ring, if present, can also be protected with other protecting groups known in the art, e.g. an acetal or a thioketal. Moreover, (17α)-17,23-epoxy-3-ethoxy-24-norchola-3,5,20-triene could be prepared directly by treatment of 3-ethoxyandrosta-3,5-dien-17-one with 4-chloro-2-lithio-1-butene (see e.g. E. Piers and V. Karunaratne, Tetrahedron 45, 1089-1104 (1989)). Finally, introduction of the 20-21 double bond into the cholane system could also be effected by an elimination reaction of an (17α,20β)-17,23-epoxy-24-norcholane precursor possessing a suitable leaving group in either the 20- or the 21-position.
a. To a solution of 25.6 g of (17β)-4',5'-dihydro-3-methoxyspiro[estra-1,3,5(10)-triene-17,2'(3'H)- furan]-3'-one (see D. Gange and Ph. Magnus, J. Am. Chem. Soc., 100 (1978), 7746-7747) in 200 ml of ethanol and 200 ml of toluene were added 2.85 g of sodium borohydride and the mixture was stirred at room temperature for 16 h. Acetic acid was added until pH 7, followed by addition of water, and the mixture was extracted with toluene. Removal of the solvent under reduced pressure afforded the crude alcohol, which was crystallized from methanol to yield 24 g of (17β,3'S)-4',5'-dihydro-3-methoxyspiro[estra-1,3,5(10)-triene-17,2',( 3'H)-furan]-3'-ol. M.p. 130°C
b. (i) A solution of 9 g of (17β,3'S)-4',5'-dihydro-3-methoxyspiro[estra-1,3,5(10)-triene-17,2'(3 'H)-furan]-3'-ol in 150 ml of tetrahydrofuran was added to a solution of 4 g of lithium in 450 ml of liquid ammonia at -33°C After stirring for 3 h at this temperature 60 ml of ethanol were added and the ammonia was allowed to evaporate. The residue was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure, affording after trituration with diisopropyl ether 8.9 g of (17β,3'S)-4',5'-dihydro-3-methoxyspiro[estra-2,5(10)-diene-17,2'(3'H) -furan]-3'-ol.
(ii) 8.9 g of the above-mentioned diene were dissolved in 65 ml of methanol and 65 ml of tetrahydrofuran. At 5°C a solution of 4.6 g of oxalic acid in 45 ml of water and 22 ml of methanol was added. After stirring for 6 h at ambient temperature the mixture was poured into an ice-cold 1% sodium hydrogen carbonate solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure to give 8.5 g of the crude (17β,3'S)-4',5'-dihydro-3'-hydroxyspiro[estr-5(10)-ene-17,2'(3'H)-fur an]-3-one.
(iii) 8.5 g of this ketone were dissolved in 90 ml of pyridine. To this solution were added portionwise 10 g of phenyltrimethylammonium tribromide during 15 min at 0°C After stirring for 3 h at room temperature the mixture was poured into 800 ml of ice-water and the product extracted with ethyl acetate. The organic layer was washed with 2M hydrochloric acid and with brine, and dried over magnesium sulfate. The residue was chromatographed after evaporation of the solvent to yield 4.7 g of (17β,3'S)-4',5'-dihydro-3'-hydroxyspiro[estra-4,9-diene-17,2'(3'H)-fu ran]-3-one. M.p. 180°C
c. (i) A mixture of 4.1 g of (17β,3'S)-4',5'-dihydro-3'-hydroxyspiro[estra-4,9-diene-17,2'(3'H)-fu ran]-3-one, 30 ml of dichloromethane, 30 ml of ethylene glycol, 10 ml of triethyl orthoformate and 200 mg para-toluenesulphonic acid was stirred for 2 h at room temperature. The reaction was stopped by the addition of water and sodium hydrogen carbonate, the layers were separated and the organic layer was washed with water. After drying over magnesium sulfate and concentration under reduced pressure 5.1 g of the crude (17β,3'S)-4',5'-dihydro-3'-hydroxyspiro[estra-4,9-diene-17,2'(3'H)-fu ran]-3-one cyclic 1,2-ethanediyl acetal were obtained, which was used in the next step without further purification.
(ii) A mixture of 5.1 g of the above-mentioned compound, 200 ml of toluene, 36 ml of cyclohexanone and 3.6 g of aluminum iso-propoxide was refluxed for 3 h. After cooling to room temperature, ethyl acetate was added and the mixture was washed repeatedly with a 75 % w/v solution of Seignette salt. The organic layer was washed with water and brine, and dried over magnesium sulfate. Evaporation of the solvent under reduced pressure followed by chromatography afforded 4 g of (17β)-4',5'-dihydrospiro[estra-5(10),9(11)-diene-17,2'(3'H)-furan]-3, 3'-dione cyclic 3-(1,2-ethanediyl acetal). M.p. 146°C
d. To a suspension of 3.09 g of methyltriphenylphosphonium bromide in 25 ml of toluene were added 0.83 g of potassium tert-butoxide. The mixture was refluxed for 45 min, and then cooled, after which a solution of 1.10 g of the acetal of c(ii) in 2 ml of toluene were added and the mixture was refluxed for 1 hour. The suspension was subsequently poured into ice-water, the toluene layer separated, washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. The residue was chromatographed to afford 0.95 g of (17α)-17,23-epoxy-19,24-dinorchola-5(10),9(11),20-trien-3-one cyclic 1,2-ethanediyl acetal. M.p. 132°C
e. (i) To a solution of 3.7 g of the acetal of d in 25 ml of dichloromethane were added 5 g of sodium hydrogen carbonate. To this mixture were added at -40°C a solution of 2.5 g of meta-chloroperbenzoic acid in 15 ml of dichloromethane. After stirring for 30 min at 0°C, the mixture was poured into ice-water and extracted with dichloromethane. The organic layer was washed with a sodium hydrogen carbonate solution and with water, dried over magnesium sulfate and concentrated under reduced pressure. The residue was chromatographed to give 1.8 g of the intermediate 5α,10α-epoxide. Alternatively, the intermediate 5α,10α-epoxide can be prepared using 30% H2 O2 /PhC(O)CF3 as described in German Patent DE 3722486.
(ii) To a solution of [4-(N,N-dimethylamino)phenyl]magnesium bromide (prepared from 4.4 g of 4-bromo-N,N-dimethylaniline and 0.6 g of magnesium) in 40 ml of tetrahydrofuran were added 0.5 g of copper-(I)chloride at room temperature. Subsequently, 1.8 g of the 5α,10α-epoxide of e(i) in 10 ml of tetrahydrofuran were added and stirring was continued for 30 min. The mixture was poured into an ammonium chloride solution and extracted with ethyl acetate. After washing with water, the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was chromatographed to afford 1.4 g of the intermediate (5α,11β,17α)-11-[(4-dimethylamino)phenyl]-17,23-epoxy-5-h ydroxy-19,24-dinorchola-9,20-dien-3-one cyclic 1,2-ethanediyl acetal.
(iii) 1.4 g of the acetal of e(ii) in 15 ml of 70% acetic acid were heated for 2 h at 50°C After cooling to room temperature the mixture was neutralized with sodium hydrogen carbonate and extracted with ethyl acetate. After drying over magnesium sulfate, the solvent was evaporated and the residue chromatographed to give 0.9 g of (11β,17α)-11-[(4-dimethylamino)phenyl]-17,23-epoxy-19,24-dinorc hola-4,9,20-trien-3-one. M.p. 168°C; [α]D20 =+125° (c=1.135, dioxane).
In an analogous manner as described in Example 11 were prepared
(11β,17α)-17,23-epoxy-11-(4-ethenylphenyl)-19,24-dinorchola-4,9, 20-trien-3-one. M.p. 191°C; [α]D20 =+128° (c=0.94, dioxane).
(11β,17α)-11-(4-acetylphenyl)-17,23-epoxy-19,24-dinorchola-4,9,2 0-trien-3-one. M.p. 126°C; [α]D20 =+82° (c=0.955, dioxane).
(11β,17α)-17,23-epoxy-11-(4-methoxyphenyl)-19,24-dinorchola-4,9, 20-trien-3-one. M.p. 185°C
(11β,17α)-17,23-epoxy-11-(4-methylthiophenyl)-19,24-dinorchola-4 ,9,20-trien-3-one. M.p. 186°C; [α]D20 =+121° (c=1.155, dioxane).
(7β,11β,17α)-11-[(4-dimethylamino)phenyl]-17,23-epoxy-7-met hyl-19,24-dinorchola-4,9,20-trien-3-one. M.p. 100°C; [α]D20 =+368° (c=1.02, dioxane).
(6β,11β17α)-11-[(4-dimethylamino)phenyl]-17,23-epoxy-6-meth yl-19,24-dinorchola-4,9,20-trien-3-one. M.p. 89°C; [α]D20 =+128° (c=1.03, dioxane).
4-[(11β,17α)-17,23-epoxy-3-oxo-19,24-dinorchola-4,9,20-trien-11- yl]benzaldehyde. M.p. 187°C
(11β,17α)-17,23-epoxy-11-[4-(4,5-dihydro-4,4-dimethyl-2-oxa-zoly l)phenyl]-19,24-dinorchola-4,9,20-trien-3-one. M.p. 240°C
4-[(11β,17α)-17,23-epoxy-3-oxo-19,24-dinorchola-4,9,20-trien-11- yl]-N-(2-hydroxy-l,l-dimethylethyl)benzamide, m.p. 170°C, was obtained after continued exposure of the above-mentioned 2-oxazolylphenyl compound to 70% acetic acid at 50°C
The E and Z-ethylidene derivatives were prepared analogously to the preparation of (11β,17α)-11-[(4-dimethylamino)phenyl]-17,23-epoxy-19,24-dinorc hola-4,9,20-trien-3-one by using ethyl triphenylphosphonium bromide. Separation by chromatography afforded: (3'E,11β,17β)-11-[(4-dimethylamino)phenyl]-3'-ethylidene-4',5'-d ihydrospiro[estra-4,9-diene-17,2' (3'H)-furan]-3-one, M.p. 175°C; [α]D20 =+128° (c=0.885, dioxane), and (3'Z,11β,17β)-11-[(4-dimethylamino)phenyl]-3'-ethylidene-4',5'-d ihydrospiro[estra-4,9-diene-17,2'(3'H)-furan]-3-one, M.p. 172°C (11β,17α)-17,23-epoxy-11-ethenyl-19,24-dinorchola-4,9,20-trien- 3-one was prepared from (17α)-17,23-epoxy-19,24]dinorchola-5(10),9(11),20-trien-3-one cyclic 1,2-ethanediyl acetal. The resulting compound was a gum.
(11β,17α)-17,23-epoxy-11-[4-(1-hydroxyethyl)phenyl]-19,24-dinorc hola-4,9,20-trien-3-one. The product was an inseparable 1:1 epimer mixture. M.p. 200°C
(11β,17α)-17,23-epoxy-11-(4-hydroxyphenyl)-19,24-dinorchola-4,9, 20-trien-3-one. [α]D20 =+58° (c=0.5, dichloromethane).
A solution of 870 mg of 4-[(11β,17α)-17,23-epoxy-3-oxo-19,24-dinorchola-4,9,20-trien-11 -yl]benzaldehyde (Example 12) and 142 mg of hydroxylamine hydrochloride in 20 ml of pyridine was stirred for 16 h at room temperature. After evaporation of the solvent the residue was chromatographed to afford 750 mg of an E/Z-isomer mixture of 4-[(11β,17α)-17,23-epoxy-3-oxo-19,24-dinorchola-4,9,20-trien-11 -yl]benzaldehyde oxime. M.p. 250°C
300 mg of the E/Z-isomer mixture of the oximes of
Example 13 were heated in 6 ml of acetic anhydride for 2 h. After removal of the solvent under reduced pressure, the residue was chromatographed to give 230 mg of 4-[(11β,17α)-17,23-epoxy-3-oxo-19,24-dinorchola-4,9,20-trien-11 -yl]benzonitrile. M.p. 218°C
A mixture of 350 mg of (11β,17α)-11-[(4-dimethylamino)phenyl]-17,23-epoxy-19,24-dinorc hola-4,9,20-trien-3-one (Example 11) and 57 mg of hydroxylamine hydrochloride in 6 ml of pyridine was heated at 90°C for 30 min. After cooling to room temperature, the mixture was poured into water, filtered, and dried to give 300 mg of a 2/1 mixture of (3E/Z,11β,17α)-11-[(4-dimethylamino)phenyl]-17,23-epoxy-19,24-d inorchola-4,9,20-trien-3-one oxime. M.p. 148°C; [α]D20 =+145° (c=1.22, dioxane).
a. A mixture of 520 mg of (5α,11β,17α)-17,23-epoxy-5-hydroxy-11-[(4-methylthio)phen yl]-19,24-dinorchola-9,20-dien-3-one cyclic 1,2-ethanediyl acetal [prepared analogously to Example 11e(ii)], 5 ml of acetone and 0.1 ml of 30% hydrogen peroxide was refluxed for 2 h. After cooling to room temperature, water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with a sodium thiosulfate solution and with water, dried over magnesium sulfate and concentrated under reduced pressure.
b. The residue of the above step (515 mg) was dissolved in 5 ml of 70% acetic acid and heated for 3 h at 50 °C After cooling to room temperature the mixture was neutralized with sodium hydrogen carbonate and extracted with ethyl acetate. After drying over magnesium sulfate, the solution was filtered over silica gel to give 250 mg of a mixture of diastereomeric sulfoxides of (11β,17α)-17,23-epoxy-11-[4-(methylsulfinyl)phenyl]-19,24-dinor chola-4,9,20-trien-3-one. Although possible, the diastereomers were not separated by chromatography. M.p. 115°C
670 mg of (11β,17α)-11-[(4-dimethylamino)phenyl]-17,23-epoxy-19,24-dinorc hola-4,9,20-trien-3-one (Example 11) were dissolved in 45 ml of ethanol under a nitrogen atmosphere. 210 mg of sodium borohydride were added and the mixture was stirred at ambient temperature for 3 h. Water was added and acetic acid until pH 7 and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was chromatographed to give (3β,11β,17α)-11-[(4-dimethylamino)phenyl]-17,23-epoxy-19,2 4-dinorchola-4,9,20-trien-3-ol. M.p. 95°C; [α]D20 =+102° (c=0.525, dioxane) and (3α,11β,17α)-11-[(4-dimethylamino)phenyl]-17,23-epoxy-19, 24-dinorchola-4,9,20-trien-3-ol. M.p. 110°C; [α]D20 =+16° (c=0.5, dioxane).
a. To a solution of 520 mg of a diastereomeric mixture of (5α,11β,17α)-17,23-epoxy-5-hydroxy-11-[4-(methylsulfinyl) phenyl]-19,24-dinorchola-9,20-dien-3-one cyclic 1,2-ethanediyl acetal (Example 16a) in 5 ml of methyl alcohol was added, at 5°C, a solution of 615 mg of oxone in 6 ml of water. After stirring for 3 h at this temperature the mixture was extracted with dichloromethane. The organic layer was washed with water, dried over magnesium sulfate and concentrated under reduced pressure.
b. The residue (520 mg) of step a) was dissolved in 5 ml of 70% acetic acid and heated for 3 h at 50°C After cooling to room temperature the mixture was neutralized with sodium hydrogen carbonate and extracted with ethyl acetate. After drying over magnesium sulfate, the solvent was removed and the residue was chromatographed to give 510 mg of (11β,17α)-17,23-epoxy-11-[4-(methylsulfonyl)phenyl]-19,24-dinor chola-4,9,20-trien-3-one. M.p. 142°C
138 mg of the 3β-alcohol (Example 17) were dissolved in 0.5 ml of pyridine and 0.25 ml of acetic anhydride was added. The mixture was stirred overnight under a nitrogen atmosphere, poured into water and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, concentrated under reduced pressure and chromatographed to afford 100 mg of (3β,11β,17α)-11-[(4-dimethylamino)phenyl]-17,23-epoxy-19,2 4-dinorchola-4,9,20-trien-3-ol acetate (ester). M.p. 148°C
a. A solution of 5 g of the epoxide of Example 11e in 15 ml of tetrahydrofuran was added at 0°C to a suspension of (2-bromo-5-methoxybenzyl)magnesium chloride (prepared from 1.15 g of magnesium and 12.4 g of 2-bromo-5-methoxybenzylchloride) in 42 ml of diethyl ether. The mixture was stirred overnight at room temperature. Work-up as described in Example 11e afforded after chromatography 4.3 g of (17α)-19-[1-(2-bromo-5-methoxy)phenyl]-17,23-epoxy-5-hydroxy-24-norc hol-9(11)-en-3-one cyclic 1,2-ethanediyl acetal.
b. A mixture of 1 g of this acetal, 0.74 ml of tri-n-butyltin hydride, 83 mg of 2,2'-azobis(2-methylpropionitrile) in 83 ml of toluene was refluxed for 3 h. After cooling to room temperature, 25 ml of a saturated potassium fluoride solution was added and stirring was continued for 1 h. The layers were separated, the water layer extracted with ethyl acetate, and the combined organic layers were washed with water and brine. After drying over magnesium sulfate and evaporation of the solvent, the residue was chromatographed to give 0.71 g of the intermediate (5α,11α,17α)-17,23-epoxy-9,11-dihydro-5-hydroxy-6'-metho xy-4'H-naphtho[3',2',1':10,9,11]-19,24-dinorchol-9(11),20-dien-3-one cyclic 1,2-ethanediyl acetal. M.p. 226°C
c. A solution of 0.7 g of this acetal in 50 ml of acetone and 2.5 ml of 4M hydrochloric acid was stirred at 40°C for 45 min. After cooling to room temperature, sodium hydrogen carbonate was added and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, the solvent removed in vacuo and the residue was chromatographed to give 0.4 g of (11α,17α)-17,23-epoxy-9,10-dihydro-6'-methoxy-4'H-naphtho[3',2 ',1':-10,9,11]-19,24-dinorchola-4,9(11),20-trien-3-one. M.p. 206°C
The intermediate of Example 11d can also be prepared by treatment of (17β)-4',5'-dihydrospiro[estra-5(10),9(11)-diene-17,2'(3'H)-furan]-3, 3'-dione cyclic 3-(1,2-ethanediyl acetal) with trimethylsilylmethylmagnesium chloride, followed by acid treatment.
a. In an analogous manner as described in Example 20a, 1.1 g of (17α)-17,23-epoxy-5-hydroxy-19-(3-methoxyphenyl)-24-norchola-9(11),2 0-dien-3-one cyclic 1,2-ethanediyl acetal were prepared. M.p. 164° C.
b. A solution of 1.1 g of the above-mentioned acetal in 50 ml of acetone containing 2.5 ml of 4M hydrochloric acid was stirred for 2 h at 40°C Work up as described in Example 20c afforded, after chromatography, 0.7 g of (17α)-17,23-epoxy-19-(3-methoxyphenyl)-24-norchola-4,9(11),20-trien- 3-one. M.p. 169°C
The intermediate of Example 11c(ii) can also be prepared by converting the known estra-5(10),9(11)-diene-3,17-dione cyclic 3-(1,2-ethanediyl acetal) (A. Belanger, D. Philibert, and G. Teutsch, Steroids 37 (1981), 361-383) in a similar manner as described by D. Gange and Ph. Magnus, J. Am. Chem. Soc. 100 (1978), 7747-7748:
(i) To 65 ml of n-butyllithium (1.6 M solution in hexane) in 48 ml of tetrahydrofuran were added at -78°C 9.3 ml of 1-methoxy-1,2-propadiene. After stirring for 45 min at this temperature 10.6 g of estra-5(10),9(11)-diene-3,17-dione cyclic 3-(1,2-ethanediyl acetal) were added. Subsequently, the mixture was stirred at -40° C. for 30 min and poured into an ice-cold ammonium chloride solution. Ethyl acetate was added and the layers were separated. The organic layer was washed with brine and dried over magnesium sulfate, and the solvent was removed under reduced pressure.
(ii) The crude 1,2-propadiene was mixed with 230 ml of tert-butanol, 3.75 g of potassium tert-butoxide and 0.3 g of dicyclohexano-18-crown-6. After refluxing for 8 h, the mixture was poured into water and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, evaporated, and the residue was chromatographed to afford 9.1 g of (17β)-3'-methoxyspiro[estra-5(10),9(11)-diene-17,2'(5'H)-furan]-3-one cyclic 1,2-ethanediyl acetal.
(iii) This enol ether was dissolved in 70 ml of acetone and a 1M hydrochloric acid solution was added until pH 2. The mixture was stirred for 3 h, subsequently poured into a sodium hydrogen carbonate solution, and extracted with ethyl acetate. After drying over magnesium sulfate and removal of the solvent, the residue was subjected to chromatography to yield 6.4 g of (17α)-4',5'-dihydro-spiro[estra-5(10),9(11)-diene-17,2'(3'H)-furan]- 3,3'-dione cyclic 3-(1,2-ethanediyl acetal).
a. To a solution of 1.2 g of (17α)-19-[1-(2-bromo-5-methoxy)phenyl]-17,23-epoxy-5-hydroxy-24-norc hola-9(11),20-dien-3-one cyclic 1,2-ethanediyl acetal (Example 20a) in 17 ml of dichloromethane were added a solution of 123 mg of sodium hydrogen carbonate in 4.6 ml of water and 400 mg of m-chloroperbenzoic acid. After stirring for 1.5 h the mixture was worked up as described in Example 11e(i). Chromatography gave 880 mg of the intermediate 9α,11α-epoxide.
b. A mixture of 880 mg of this epoxide, methylmagnesium iodide (prepared from 220 mg of magnesium and 0.9 ml of methyl iodide in 9 ml of diethyl ether) and 17.5 ml of n-butyllithium (1.6M solution in hexane) was stirred for 16 h at room temperature. Work up as described in Example 11e(ii) afforded the crude 9-hydroxy 3-acetal derivative, which was dissolved in 50 ml of acetone containing 2.5 ml of 4M hydrochloric acid. After stirring for 45 min at 40°C the mixture was worked up as described in Example 20c to yield after purification by chromatography 50 mg of (9α,11α,17α)-17,23-epoxy-9,11-dihydro-9-hydroxy-6'-metho xy-4'H-naphtho[3',2',1':10 9 11]-19 24-dinorchola-4,9(11),20-trien-3-one. [α]D20 =-6° (c=1.0, dioxane).
The intermediate of Example 11d can also be prepared in one step by a reaction of estra-5(10),9(11)-dien-3,17-dione cyclic 3-(1,2-ethanediyl acetal) with 4-chloro-2-lithio-1-butene.
a. To a solution of 1.5 ml of 1-methoxy-1,2-propadiene in 21 ml of tetrahydrofuran were added 10.2 ml of n-butyllithium (1.6M solution in hexane) at -78°C After stirring for 45 min, 2.2 g of (11β)-11-(4-methoxyphenyl)-estr-5-en-3,17-dione cyclic 3-(1,2-ethanediyl acetal) (described in German patent application DE 4018167) were added and stirring was continued for 1 h at -78°C and 45 min at -30°C The mixture was poured into water, ethyl acetate was added and the layers were separated. The organic layer was washed with brine, dried over magnesium sulfate, and the solvent was removed under reduced pressure.
b. This crude 1,2-propadiene was mixed with 75 ml of tert-butanol, 0.65 g of potassium tert-butoxide and 0.3 g of dicyclohexano-18-crown-6. After refluxing for 16 h, the mixture was poured into water and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, evaporated, and the residue was chromatographed to afford 2.5 g of (11β,17β)-3'-methoxy-11-(4-methoxyphenyl)spiro[estr[5]ene-17,2'( 5'H)-furan]-3-one cyclic 1,2-ethanediyl acetal.
c. TO a stirred suspension of 7.5 g of silica gel and 0.75 ml of a saturated aqueous oxalic acid solution in 15 ml of dichloromethane were added 2.5 g of the above-mentioned methyl enolether. After stirring for 1 h at room temperature the mixture was filtered and the silica gel was washed with dichloromethane containing 5% of methanol. The filtrate was washed with a sodium hydrogen carbonate solution and with water and dried over magnesium sulfate. Chromatography afforded 2.1 g of (11β,17β)-4',5'-dihydro-11-(4-methoxyphenyl)spiro[estr[5]ene-17, 2'-(3'H)-furan]-3,3'-dione cyclic 3-(1,2-ethanediyl acetal). M.p. 175°C
d. To a suspension of 1.6 g of methyltriphenylphosphonium bromide in 15 ml of toluene were added 0.43 g of potassium tert-butoxide. The mixture was refluxed for 45 min, cooled to room temperature, after which a solution of 1.4 g of the above-mentioned acetal (Example 26c) in 10 ml of toluene were added and the mixture was refluxed for 45 min. The suspension was poured into ice water, the toluene layer separated, washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. The residue was chromatographed to yield 1 g of (11β,17α)-17,23-epoxy-11-(4-methoxyphenyl)-19,24-dinorchola-5,2 0-dien-3-one cyclic 1,2-ethanediyl acetal. M.p. 179°C
e. A mixture of 1 g of the above-mentioned acetal, 50 ml of acetone and 2.5 ml of 4M hydrochloric acid was stirred for 2 h at 40° c. After cooling to room temperature, the mixture was neutralized with sodium hydrogen carbonate and extracted with ethyl acetate. After drying over magnesium sulfate and concentration, chromatography afforded 0.8 g of (11β,17α)-17,23-epoxy-11-(4-methoxyphenyl)-19,24-dinorchola-4,2 0-dien-3-one. M.p. 185.5°C
In an analogous manner as described in Example 26 were prepared: (11β,17α)-11-[4-(dimethylamino)phenyl]-17,23-epoxy-19,24-dinorc hola-4,20-dien-3-one from (11β)-11-[4-(dimethylamino)phenyl]-estr-5-ene-3,17-dione cyclic 3-(1,2-ethanediyl acetal). [α]D20 =+25° (c=1.025 dioxane).
(11β,17α)-17,23-epoxy-11-(4-methoxyphenyl)-19,24-dinorchola-4,15 ,20-trien-3-one from (11β)-11-(4-methoxy-phenyl)-estra-5,15-diene-3,17-dione cyclic 3-(1,2-ethanediyl acetal) (DE 4042004). M.p. 166°C
(11β,17β,3'E)-3'-ethylidene-4',5'-dihydro-11-(4-methoxy phenyl)spiro[estr-4-ene-17,2'(3'H)-furan]-3-one (M.p. 184°C) and (11β,17β,3'Z)-3'-ethylidene-4',5'-dihydro-11-(4-methoxyphenyl)sp iro[estr-4-ene-17,2'(3'H)-furan]-3-one (M.p. 174°C) from (11β,17β)-4',5'-dihydro-11-(4-methoxyphenyl)spiro[estr-5-ene-17, 2'(3'H)-furan]-3,3'-dione cyclic 3-(1,2-ethanediyl acetal) (Example 26c) by treatment with ethyl triphenylphosphonium iodide, followed by separation by chromatography.
a. A mixture of 1.4 g of the acetal of Example 26d, 0.84 g of sodium thiomethoxide and 10 ml of N,N-dimethyl-formamide was refluxed for 3 h. Work-up as described in Example 11e afforded after chromatography 1 g of (11β,17α)-17,23-epoxy-11-(4-hydroxyphenyl)-19,24-dinorchola-5,2 0-dien-3-one cyclic 1,2-ethanediyl acetal. M.p. 222°C
b. A solution of 1 g of this acetal in 50 ml of acetone and 2.5 ml of 4M hydrochloric acid was stirred for 2 h at 40°C After cooling sodium hydrogen carbonate was added and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, concentrated, and the residue was chromatographed to afford 0.75 g of (11β,17α)-17,23-epoxy-11-(4-hydroxyphenyl)-19,24-dinorchola-4,2 0-dien-3-one. M.p. 149°C
a. To a solution of 5.46 g of the acetal of Example 28a and 2.1 ml of triethylamine in 120 ml of dichloromethane were added 2.3 ml of trifluoromethanesulfonic anhydride at 0°C After 30 min stirring at this temperature the mixture was poured into a sodium hydrogen carbonate solution, the layers were separated, and the organic layer was washed with water and brine. Drying over magnesium sulfate, evaporation of the solvent and chromatography yielded 6.8 g of 4-[(11β,17α)-17,23-epoxy-3,3-[1,2-ethanediylbis(oxy)]-19,24-din orchola-5,20-dien-11-yl]phenol trifluoromethanesulfonate. M.p. 198° C.
b. A suspension of 2.2 g of the triflate obtained above and 0.3 g of lithium chloride in 28 ml of N,N-dimethylformamide was stirred for 15 min at room temperature. Subsequently, 0.22 g of tetrakis(triphenylphosphine)palladium(0) and 1.3 ml of (1-ethoxyvinyl)tributyltin were added and the mixture was refluxed for 3 h. After cooling, the suspension was diluted with ethyl acetate and filtered over celite, which was washed thoroughly with ethyl acetate. The filtrate was treated with brine, and dried over magnesium sulfate. Removal of the solvent gave 1.4 g of the crude acetal, which was used in the next step without further purification.
c. A mixture of 1.4 g of the above-mentioned acetal, 70 ml of acetone and 3.5 ml of 4M hydrochloric acid was stirred for 2 h at 40°C Work-up as described in Example 11e gave, after chromatography, 1 g of (11β,17α)-11-(4-acetylphenyl)-17,23-epoxy-19,24-dinorchola-4,20 -dien-3-one. M.p. 223°C
a. A suspension of 2.2 g of the triflate of Example 29a and 0.48 g of lithium chloride in 75 ml of dioxane was stirred for 15 min at room temperature. Subsequently, 0.22 g of tetrakis(triphenylphosphine)palladium(0) and 5.6 ml of bis(tributyl)tin were added and the mixture was refluxed for 2 h. After cooling, 6.75 g of 4-bromobenzonitrile were added and refluxing was continued for 24 h. The mixture was poured into brine and ethyl acetate was added. The organic layer was separated, dried over magnesium sulfate and evaporated. The residue was purified by chromatography to afford 1.3 g of 4'-[(11β,17α)-17,23-epoxy-3,3-[1,2-ethanediylbis(oxy)]-19,24-di norchola-5,20-dien-11-yl]-1,1'-biphenyl-4-carbonitrile.
b. A mixture of 1.3 g of the above-mentioned nitrile in 65 ml of acetone and 3.25 ml of 4M hydrochloric acid was stirred at 40°C for 2 h. Work-up as described in Example 11e produced, after chromatography, 0.7 g of 4'-[(11β,17α)-17,23-epoxy-3-oxo-19,24-dinorchola-4,20-dien-11-y l]-1,1'-biphenyl-4-carbonitrile. M.p. 177°C
a. A mixture of 2.2 g of the triflate of Example 29a, 32 ml of toluene, 15 ml of ethanol, 0.59 g of diethyl (3-pyridyl)borate, 0.4 g of lithium chloride, 0.27 g of tetrakis(triphenylphosphine)palladium(0) and 6 ml of a 2M aqueous sodium carbonate solution was refluxed for 2.5 h. After cooling, ethyl acetate and brine were added and the layers separated. The organic layer was washed with brine, dried over magnesium sulfate and the solvent was removed under reduced pressure. The residue was chromatographed to afford 2 g of (11α,17α)-17,23-epoxy-11-[4-(3-pyridinyl)phenyl]-19,24-dinorch ola-5,20-dien-3-one cyclic 1,2-ethanediyl acetal.
b. A mixture of 2 g of this acetal, 100 ml of acetone and 5 ml of 4M hydrochloric acid was stirred for 2 h at 40°C Work up as described in Example 11e gave 1 g of (11β,17α)-17,23-epoxy-11-[4-(3-pyridinyl)phenyl]-19,24-dinorcho la-4,20-dien-3-one. M.p. 255°C
a. To a mixture of 1.2 g of (11β,17α)-17,23-epoxy-11-(4-methoxyphenyl)-19,24-dinorchola-4,2 0-dien-3-one (Example 26e), 30 ml of tetrahydrofuran, 0.4 ml of trimethylorthoformate, and 3.3 ml of methanol were added 0.6 ml of boron trifluoride etherate at 0°C After stirring for 6 h at this temperature, pyridine was added and the mixture was evaporated under reduced pressure. The residue was chromatographed to afford 1 g of methyl dienol ether.
b. To a solution of 1 g of this methyl dienol ether in 10 ml of acetonitrile were added 800 mg of palladium(II)acetate. The mixture was stirred for 16 h at room temperature and subsequently filtered over celite. After washing the celite with ethyl acetate, the filtrate was concentrated under reduced pressure. The residue was purified by chromatography to give 350 mg of (11β,17α)-17,23-epoxy-11-(4-methoxyphenyl)-19,24-dinorchola-4,6 ,20-trien-3-one. M.p. 225°C
a. To a solution of 1 g of the acetal of Example 26d in 10 ml of dichloromethane containing 0.1 ml of pyridine were added at 0°C 0.1 ml of hexachloroacetone followed by 1 ml of 30% hydrogen peroxide. The mixture was stirred at room temperature for 7 days. After this period, water and dichloromethane were added; the layers were separated, and the organic layer was washed with a sodium thiosulfate solution and water. The solution was dried over magnesium sulfate, the solvent was evaporated, and the residue chromatographed to afford 0.53 g of the intermediate 5α,6α-epoxide. M.p. 223°C
b. To a solution of 0.53 g of this epoxide in 3 ml of tetrahydrofuran were added 4.7 ml of a methylmagnesium chloride solution (3M in tetrahydrofuran) at -20°C The mixture was stirred for 16 h at room temperature, poured slowly into an ice-cold ammonium chloride solution, and extracted with ethyl acetate. The organic layer was washed with brine and dried over magnesium sulfate and the solvent was removed under reduced pressure. The crude (5α,6β,11β,17α)-17,23-epoxy-5-hydroxy-11-(4-methoxyp henyl)-6-methyl-19,24-dinorchola-20-en-3-one cyclic 1,2-ethanediyl acetal (0.55 g) was used in the next steps without further purification.
c. A mixture of 0.2 g of this acetal, 0.5 ml of 4M hydrochloric acid and 10 ml of acetone was stirred for 2 h at 40°C Work-up as described in Example 26e afforded, after chromatography, 0.12 g of (6α,11β,17α)-17,23-epoxy-11-(4-methoxyphenyl)-6-methyl-19 ,24-dinorchola-4,20-dien-3-one. M.p. 209°C
d. A mixture of 0.3 g of the acetal of b, 15 ml of acetone and 1.5 ml of 4M hydrochloric acid was stirred for 2 h at 0°C Work-up as described in Example 26e afforded after chromatography, 0.25 g of (5α,6β,11β,17α)-17,23-epoxy-5-hydroxy-11-(4-methoxyp henyl)-6-methyl-19,24-dinorchol-20-en-3-one.
e. A mixture of 0.15 g of the 5-hydroxy derivative of d, 6 ml of ethanol and 0.3 ml of 0.1M sodium hydroxide was stirred for 4.5 h at room temperature. Subsequently, the solution was poured into a saturated ammonium chloride solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and the solvent removed under reduced pressure. Chromatography afforded 0.08 g of (6β,11β,17α)-17,23-epoxy-11-(methoxyphenyl)-6-methyl-19,24 -dinorchola-4,20-dien-3-one. M.p. 201°C
(17α)-17,24-epoxy-13-ethyl-18,19-dinorchola-4,20-dien-3-one was prepared from 3-ethoxy-13-ethylgona-3,5-dien-17-one as follows:
a. A solution of 20.2 g of 2-bromo-5-trimethylsilyloxy-1-pentene in 340 ml of dry ether was cooled to -78°C, and 100 ml of a tert-butyllithium solution (1.7M in pentane) were added dropwise. After 15 min, 21.35 g of the steroid mentioned above were added; the mixture was then allowed to warm to 0°C over a period of 2 h. Subsequently, the reaction mixture was poured into a saturated aqueous solution of ammonium chloride, which was extracted three times with ethyl acetate. The combined extracts were washed with a solution of sodium bicarbonate and with brine, dried over sodium sulfate, and concentrated under reduced pressure to afford 28.9 g (88%) of the desired (17α)-3-ethoxy-13-ethyl-24-trimethylsilyloxy-18,19-dinorchola-3,5,20 -trien-17-ol, which was used in the next step without further purification.
b. 28.9 g of the alcohol described above were dissolved in a mixture of 1100 ml of acetone, 11 ml of water and 11 ml of concentrated hydrochloric acid, and the mixture stirred at room temperature for 2 h. Sodium bicarbonate solution was then added, and the acetone removed under reduced pressure. The residue was extracted three times with ether; the combined extracts were washed with bicarbonate solution and with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was chromatographed to afford 7.86 g (33%) of (17α)-13-ethyl-17,24-dihydroxy-18,19-dinorchola-4,20-dien-3-one.
c. To a solution of 3.27 g of the diol obtained in the previous step and 5.8 ml of s-collidine in 18 ml of dry dichloromethane were dropwise added 1.05 ml of methanesulfonyl chloride. The mixture was then stirred at room temperature for 45 min, after which period the reaction mixture was poured into water; this was extracted three times with ethyl acetate; the combined extracts were washed with water (four times) and with brine, and dried over sodium sulfate. The solvent was removed by evaporation under reduced pressure, and the residue taken up in a mixture of 5.8 ml of s-collidine and 40 ml of dry toluene. The solution was refluxed for 1 h, after which it was poured into water. Extraction with ethyl acetate, washing of the combined extracts with brine, drying over sodium sulfate and evaporation of the solvent left a residue which was purified by chromatography to afford 2.1 g (67%) of (17α)-17,24-epoxy-13-ethyl-18,19-dinorchola-4,20-dien-3-one. M.p. 167.1°C [α]D20 =-34.8 (c=1.0, chloroform).
In a similar manner as in Example 34 were prepared
(17α)-17,24-epoxy-19-norchola-4,20-dien-3-one from 3-ethoxyestra-3,5-dien-17-one. M.p. 170.5°C [α]D20 =-31° (c=1.0, chloroform).
(17α)-17,24-epoxy-11-methylene-19-norchola-4,20-dien-3-one from 11-methyleneestr-4-ene-3,17-dione 3-cyclic 1,2-ethanediyl acetal. M.p. 177°C [α]D20 =+86° (c=1.0, chloroform).
(17α)-17,24-epoxy-11-methylene-19-norchola-4,15,20-trien-3-one from 11-methyleneestra-4,15-diene-3,17-dione 3-cyclic 1,2-ethanediyl acetal. M.p. 194.5°C [α]D20 =+2.8° (c=1.0, chloroform).
(11β,17α)-17,24-epoxy-11-methyl-19-norchola-4,20-dien-3-one from (11β)-11-methylestr-4-ene-3,17-dione 3-cyclic 1,2-ethanediyl acetal. M.p. 200°C [α]D20 =+4.4° (c=1.0, chloroform).
(11β,17α)-17,24-epoxy-11-(4-methoxyphenyl)-19-norchola-4,20-dien -3-one from (11β)-11-(4-methoxyphenyl)estr-5-ene-3,17-dione cyclic 3-(1,2-ethanediyl acetal). M.p. 169°C
a. (17α)-17-hydroxy-24-trimethylsilyloxy-19-norchola-5(10),9(11),20-tri en-3-one cyclic 1,2-ethanediyl acetal was prepared from 44 g of estra-5(10),9(11)dien-3,17-dione cyclic 3-(1,2-ethanediyl acetal) [A. Belanger et al. Steroids 37 (1981), 361-383]as described in Example 34a.
b. The crude product of the previous step was dissolved in 500 ml of tetrahydrofuran and added to a suspension of 22 g of potassium fluoride and 2.6 g of 18-crown-6 in 250 ml of tetrahydrofuran. After stirring at room temperature for 1 h, water and ethyl acetate were added, the layers were separated, and the organic layer was washed with brine and dried over magnesium sulfate. Concentration in vacuo followed by chromatography afforded 21 g of estra-5(10),9(11)dien-3,17-dione cyclic 3-(1,2-ethanediyl acetal) and 25 g of (17α)-17,24-dihydroxy-19-norchola-5(10),9(11),20-trien-3-one 3-cyclic 1,2-ethanediyl acetal.
c. To a solution of 25 g of (17α)-17,24-dihydroxy-19-norchola-5(10),9(11),20-trien-3-one cyclic 1,2-ethanediyl acetal in 107 ml of dichloromethane and 54 ml of pyridine were added 6.4 ml of methanesulfonyl chloride at 0°C, and stirring was continued at room temperature for 2 h. The reaction mixture was poured into a sodium hydrogen carbonate solution, ethyl acetate was added and the layers were separated. The organic layer was washed with brine, dried over magnesium sulfate and the solvent was removed under reduced pressure affording 35 g of crude (17α)-17-hydroxy-24-methanesulfonyloxy-19-norchola-5(10),9(11),20-tr ien-3-one cyclic 1,2-ethanediyl acetal.
d. 35 g of this crude mesylate were dissolved in 275 ml of toluene and 40 ml of collidine and the solution was refluxed for 2 h. Subsequently, the reaction mixture was poured into a sodium hydrogen carbonate solution, ethyl acetate was added and the layers were separated. The organic layer was washed with brine and dried over magnesium sulfate. After concentration in vacuo, chromatography afforded 15 g of (17α)-17,24-epoxy-19-norchola-5(10),9(11),20-trien-3-one cyclic 1,2-ethanediyl acetal.
e. A mixture of 3.8 g of the above-mentioned acetal, 0.3 ml of pyridine, 1 ml of α,α,α-trifluoroacetophenone, 57 ml of dichloromethane and 13.5 ml of 30% hydrogen peroxide was stirred for 3 days at room temperature. Subsequently, dichloromethane and water were added, the layers were separated, and the organic layer was washed with a sodium thiosulfate solution and water. After drying over magnesium sulfate and evaporation of the solvent, the residue was chromatographed to give 3 g of the intermediate 5α,10α-epoxide.
f. To a solution of [(4-dimethylamino)phenyl]magnesium bromide (prepared from 1.5 g of 4-bromo-N,N-dimethylaniline and 185 mg of magnesium) in 6 ml of tetrahydrofuran were added 21 mg of copper(I)chloride at room temperature. Subsequently, 623 mg of the 5α,10α-epoxide of Example 34e in 5 ml of tetrahydrofuran were added and stirring was continued for 1 h. The mixture was poured into an ammonium chloride solution and extracted with ethyl acetate. After washing with water, the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was chromatographed to afford 727 mg of the intermediate (5α,11β,17α)-11-[4-(dimethylamino)phenyl]-17,24-epoxy-5-h ydroxy-19-norchola-9,20-dien-3-one cyclic 1,2-ethanediyl acetal. M.p. 179°C
g. 562 mg of the acetal of 34f in 5 ml of 70% acetic acid were heated for 1 h at 50°C After cooling to room temperature the mixture was neutralized with sodium hydrogen carbonate and extracted with ethyl acetate. After drying over magnesium sulfate, the solvent was evaporated and the residue chromatographed to give 447 mg of (11β,17α)-11-[4-(dimethylamino)phenyl]-17,24-epoxy-19-norchola- 4,9,20-trien-3-one. M.p. 158°C
In an analogous manner as described in Example 36 were prepared
(11β,17α)-17,24-epoxy-11-(4-methoxyphenyl)-19-norchola-4,9,20-tr ien-3-one. M.p. 116°C
(11β,17α)-11-(4-acetylphenyl)-17,24-epoxy-19-norchola-4,9,20-tri en-3-one. M.p. 154°C
(11β,17α)-17,24-epoxy-11-(4-methylthiophenyl)-19-norchola-4,9,20 -trien-3-one. M.p. 153°C
(11S,17α)-17,24-epoxy-11-[4-(1-methylethyl)phenyl]-19-norchola-4,9,20 -trien-3-one. M.p. 130°C
Rewinkel, Johannes Bernardus Maria, Orlemans, Everardus Otto Maria, Hamersma, Johannes Antonius Maria
| Patent | Priority | Assignee | Title |
| 10155004, | Jul 20 2009 | Bayer Intellectual Property GmbH | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases |
| 8053426, | Nov 15 2006 | Bayer Intellectual Property GmbH | Progesterone receptor antagonists |
| 8278469, | Jul 20 2009 | Bayer Intellectual Property GmbH | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases |
| 8969328, | Feb 10 2010 | Bayer Intellectual Property GmbH | Progesterone receptor antagonists |
| 9085603, | Feb 10 2010 | Bayer Intellectual Property GmbH | Progesterone receptor antagonists |
| 9096639, | Jul 20 2009 | BAYER PHARMA AKTIENGESELLSCHAFT | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases |
| 9096640, | Jul 20 2009 | Bayer Intellectual Property GmbH | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-methylene oxyalkylene aryl derivatives, process for preparation thereof, and use thereof for treatment of diseases |
| 9102701, | Jul 21 2009 | Bayer Intellectual Property GmbH | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-ethynylphenyl derivatives, methods for the production thereof and use thereof for treating diseases |
| 9109004, | Feb 10 2010 | Bayer Intellectual Property GmbH | Progesterone receptor antagonists |
| 9156877, | Jul 20 2009 | Bayer Intellectual Property GmbH | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzylidene derivatives, methods for the production thereof and use thereof for treating diseases |
| 9206219, | Jul 21 2009 | Bayer Intellectual Property GmbH | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases |
| Patent | Priority | Assignee | Title |
| 2744122, | |||
| 3280157, | |||
| 3338892, | |||
| 3478067, | |||
| 3764596, | |||
| 3927046, | |||
| 4081537, | Oct 10 1975 | Schering Aktiengesellschaft | Δ15 -Steroids and pharmaceutical compositions thereof |
| 4386085, | Jan 09 1981 | POPULATION COUNCIL, INC , THE | Novel steroids |
| 5272140, | Jan 23 1987 | Akzo N.V. | 11-aryl steroid derivatives |
| 5292878, | Dec 20 1991 | N V ORGANON | 17-spirofuran-3'-ylidene steroids |
| BE623844, | |||
| EP116974, | |||
| EP277089, | |||
| EP289073, | |||
| EP321010, | |||
| EP404283, | |||
| EP549041A1, | |||
| NL7302540, | |||
| WO8705908, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jul 12 1993 | HAMERSMA, JOHANNES J A M | Akzo N V | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 006644 | /0504 | |
| Jul 12 1993 | ORLEMANS, EVERARDUS O M | Akzo N V | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 006644 | /0504 | |
| Jul 12 1993 | REWINKEL, JOHANNES B M | Akzo N V | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 006644 | /0504 | |
| Jul 28 1993 | Akzo Nobel N.V. | (assignment on the face of the patent) | / | |||
| Feb 25 1994 | Akzo N V | Akzo Nobel N V | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 007922 | /0541 | |
| Jan 12 2007 | Akzo Nobel N V | N V ORGANON | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018816 | /0737 |
| Date | Maintenance Fee Events |
| Jun 26 2001 | M183: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Jun 28 2005 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Aug 03 2009 | REM: Maintenance Fee Reminder Mailed. |
| Jan 27 2010 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Jan 27 2001 | 4 years fee payment window open |
| Jul 27 2001 | 6 months grace period start (w surcharge) |
| Jan 27 2002 | patent expiry (for year 4) |
| Jan 27 2004 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jan 27 2005 | 8 years fee payment window open |
| Jul 27 2005 | 6 months grace period start (w surcharge) |
| Jan 27 2006 | patent expiry (for year 8) |
| Jan 27 2008 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jan 27 2009 | 12 years fee payment window open |
| Jul 27 2009 | 6 months grace period start (w surcharge) |
| Jan 27 2010 | patent expiry (for year 12) |
| Jan 27 2012 | 2 years to revive unintentionally abandoned end. (for year 12) |